Open an account

Nanobiotix SA

NBTX · NYSE

$29.36+$0.17 (+0.58%)TodayMarket closed ·
Prev close $29.19

About NBTX

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company employs 97 full-time employees The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Employees
100
Headquarters
Paris, Ile-De-France
Listed
Oct 29, 2012
Sector
Health Care
Industry
Biotechnology
Website
nanobiotix.com

NBTX key statistics

Market cap
1.32B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
159.89K
Volume
69.42K
Open price
$29.13
High today
$29.54
Low today
$28.36
52 Week high
$57.14
52 Week low
$14.78

Nanobiotix SA (NBTX) at a glance

As of Oct 23, 2026, Nanobiotix SA (NBTX) shares are priced at $29.36, giving the company a market cap of 1.32B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $28.36 and $29.54. The current price is 3.5% above the day's low and 0.6% below its high.

Volume so far is 69.42K shares, below the average of 159.89K shares a day.

Over the past year Nanobiotix SA has ranged from $14.78 to $57.14, and now sits 34% of the way up that range.

Nanobiotix SA met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.70 per share against an estimate of -$0.1173.

The average analyst price target is $56.39, 92.1% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 8 analystsAvg $56.39
Low
$43.37
Now
$29.36
High
$67.63

NBTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 65.2% on average.

  1. Q2 FY22: reported -$0.76 per share against an estimate of -$0.714
  2. Q2 FY23: reported -$0.80 per share against an estimate of -$0.7344
  3. Q4 FY23: reported -$0.28 per share against an estimate of $0.102
  4. Q2 FY24: reported -$0.46 per share against an estimate of -$0.2091
  5. Q4 FY24: reported -$0.98 per share against an estimate of -$0.5457
  6. Q2 FY25: reported -$0.11 per share against an estimate of -$0.3162
  7. Q4 FY25: reported -$0.39 per share against an estimate of $0.5559
  8. Q2 FY26: reported -$0.70 per share against an estimate of -$0.1173

NBTX news

  • Avi Kapoor

    XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • Vandana Singh

    Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • Press releasePRNewswire

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

  • Avi Kapoor

    Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.